The AMA’s Historic Health Fraud and Alternative Medicine Collection includes images of quack devices from the early 20th century that generated oversight we now take for granted.
AMA J Ethics. 2021;23(9):E721-738. doi:
10.1001/amajethics.2021.721.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Jessica H. Ballou, MD, MPH and Karen J. Brasel, MD, MPH
Calls to expand palliative care education have been explicit since the 1990s, but palliative care training in surgery remains too narrowly focused on end of life.
AMA J Ethics. 2021;23(10):E800-805. doi:
10.1001/amajethics.2021.800.
Priorities far beyond generating morbidity or mortality data are needed to improve patients’ experiences, innovate metrics, and advance surgical palliation as a field.
AMA J Ethics. 2021;23(10):E806-810. doi:
10.1001/amajethics.2021.806.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"